LAVA Therapeutics Announces Acquisition by XOMA Corporation

LAVA Therapeutics ( (LVTX) ) has issued an announcement.

On August 13, 2025, LAVA Therapeutics announced its acquisition by XOMA Royalty Corporation, with the transaction expected to close in the fourth quarter of 2025. The acquisition, valued at between $1.16 and $1.24 per share, includes a contingent value right related to LAVA’s partnered and unpartnered programs. Additionally, LAVA has decided to discontinue the development of its LAVA-1266 program for acute myeloid leukemia and myelodysplastic syndrome, reflecting a strategic shift in its operations. The company reported a net loss of $8.6 million for the second quarter of 2025, with decreased research and development expenses due to restructuring activities.

The most recent analyst rating on (LVTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on LAVA Therapeutics stock, see the LVTX Stock Forecast page.

Spark’s Take on LVTX Stock

According to Spark, TipRanks’ AI Analyst, LVTX is a Neutral.

The stock score reflects significant financial challenges, offset by positive technical indicators and corporate events. The financial performance is the most significant risk, while shareholder confidence and technical strength provide some optimism.

To see Spark’s full report on LVTX stock, click here.

More about LAVA Therapeutics

LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® bispecific gamma delta T cell engagers. The company operates in the biotechnology industry with a focus on cancer treatment.

Average Trading Volume: 70,046

Technical Sentiment Signal: Hold

Current Market Cap: $40.25M

Find detailed analytics on LVTX stock on TipRanks’ Stock Analysis page.